Zurueck zur Suche

Reporte zur Charge N6201

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

3Reporte angezeigt
0Todesfaelle
0Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
NJ 1 FL 1 PA 1

VAERS 1261574

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge N6201

moderat
Staat
NJ
Alter
-
Geschlecht
U
Eingang
27.02.2022
Impfdatum
14.02.2021
Beginn
15.02.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
- / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Dizziness Feeling abnormal Orthostatic hypotension Vertigo

Symptomtext

severe dizziness / light headed; room spinning; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 66 year-old patient received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 14Feb2021 17:00 (Lot number: EN6201) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Basal cell carcinoma", start date: May1997, stop date: Jun2019; "Osteoporosis", start date: Jun2019 (ongoing); "Skin R arm removed" (unspecified if ongoing); "Abdominal Bruit" (unspecified if ongoing). Concomitant medication(s) included: LIPITONE taken for abdominal bruit (ongoing); ASA taken for abdominal bruit (ongoing). The following information was reported: DIZZINESS (non-serious) with onset 15Feb2021, outcome "recovered" (Feb2021), described as "severe dizziness / light headed"; VERTIGO (non-serious) with onset 15Feb2021, outcome "recovered" (Feb2021), described as "room spinning". Therapeutic measures were not taken as a result of dizziness, vertigo. Additional information: It was further reported that the patient was exercising weight lifting and experienced severe dizziness, room spinning, and light headed. Patient do this series of exercise almost daily and had never experienced these symptoms. Dizziness lasted approximately 3 to 4 hours. The patient received the second dose of BNT162B2 (Lot number: EN6206) intramuscularly in the left arm on 07Mar2021 at 17:00. No follow-up attempts are possible. No further information is expected.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Orthostatic hypotension
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Osteoporosis
Vorgeschichte
Medical History/Concurrent Conditions: Abdominal bruit; Basal cell carcinoma; Skin operation
Andere Medikamente
LIPITONE; ASA
Allergien
-
Vorherige Impfungen
-

VAERS 1531018

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge N6201

mild
Staat
FL
Alter
70,0
Geschlecht
F
Eingang
06.08.2021
Impfdatum
26.02.2021
Beginn
27.02.2021
Tage bis Beginn
1,0
Dosis
2
Route/Site
- / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Dermatitis Erythema Pruritus Rash

Symptomtext

Inflamed skin; Rash face, neck arms and ears; Itchy skin; Red skin; Rash face, neck arms and ears; Rash face, neck arms and ears; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: N6201) via an unspecified route on 26Feb2021 at 12:00 hours in left arm (at an age of 70-year-old) as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. The medical history included pollen allergy. The patient received calcium (MANUFACTURER UNKNOWN), retinol (VITAMIN A), colecalciferol (VITAMIN D3) received on unknown dates within two weeks of vaccination for unknown indications. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN5318) via an unspecified route on 03Feb2021 in left arm at 10:30 hours as single dose for COVID-19 immunisation. Post the vaccination, the patient was not tested for COVID-19. On 27Feb2021, the patient experienced rash face, neck, arms and ears, itch and red or inflamed skin. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included treatment with topical cream and a ten days course of prednisone. The clinical outcome of the events of inflamed skin, rash face, neck, arms and ears, itchy skin and red skin was recovered on an unknown date in 2021. No follow-up attempts are needed. No further information is expected.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pruritus
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
Medical History/Concurrent Conditions: Pollen allergy (known_allergies: pollen)
Andere Medikamente
Vitamin a; VITAMINS D3; CALCIUM
Allergien
-
Vorherige Impfungen
-

VAERS 1337630

PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge N6201

gering
Staat
PA
Alter
67,0
Geschlecht
F
Eingang
21.05.2021
Impfdatum
01.02.2021
Beginn
02.05.2021
Tage bis Beginn
90,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Rhinorrhoea SARS-CoV-2 test

Symptomtext

Congestion or runny nose Contacts Type Contact Phone User 05/08/2021 09:59 AM Phone (Outgoing) (Self) RN Care Coordination Progress Note RN (Registered Nurse) COVID 19 MAB Infusion Navigator Post Infusion Outreach #1 Infusion Date: 5/7/21 Medication ? bamlanivimab/etesevimab ? casirivimab ? bamlanivimab Tell me how you are feeling today? Feeling fine, no reported side effects from infusion. O2 reported as 94%. No reported fevers. Eating and drinking okay. Navigator reviewed isolation guidelines and protocols. Patient with no further questions or concerns at this time. We recommend that you have a follow-up with your family doctor, especially if your symptoms are not improving. This can be by video/telephone or in person, dependent on the office preference. Inform the office that you have received a COVID monoclonal antibody infusion. The office will let you know when and how to follow-up. Please call your provider/physician to schedule a follow-up appointment. I will be calling you in another couple of days on 5/17. Please continue to monitor your temperature and pulse ox (oxygen level). If everything is going well, we will plan for you to graduate from monitoring around day 10 after your infusion. Reminder: There is a possible risk of reduced immune response to the COVID vaccine. COVID vaccination should be delayed for at least 90 days after you receive the infusion.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rhinorrhoea
Hospital-Tage
-
Labordaten
05/06/21 0503 COVID-19 (SARS CoV-2,RNA Molecular Amplification) Collected: 05/05/21 1537 | Final result | Specimen: Swab from Nares COVID-19 SARS-CoV-2 Overall Result DetectedCritical
Aktuelle Erkrankungen
-
Vorgeschichte
Circulatory Palpitations Mitral valve prolapse Essential hypertension Digestive Vitamin D deficiency Musculoskeletal Osteopenia History of vertebral compression fracture Endocrine/Metabolic Pure hypercholesterolemia Other History of cervical dysplasia History of pelvic fracture Adjustment disorder with mixed emotional features
Andere Medikamente
amLODIPine (NORVASC) 5 mg tablet atorvastatin (LIPITOR) 20 mg tablet buPROPion XL (WELLBUTRIN XL) 150 mg 24 hr tablet cholecalciferol, vitamin D3, 50 mcg (2,000 unit) tablet tablet conjugated estrogens (PREMARIN) vaginal cream lisinopriL (Z
Allergien
NKA
Vorherige Impfungen
-